癌症睾丸抗原 FBXO39 预测预后不良，并与胶质瘤的干性和侵袭性相关。
The cancer-testis antigen FBXO39 predicts poor prognosis and is associated with stemness and aggressiveness in glioma.
机构信息
State Key Laboratory of Cancer Biology, Department of Pathology, Xijing Hospital and School of Basic Medicine, Fourth Military Medical University, Xi'an, China.
Military Medicine and Special Subject, No. 971 Hospital of the PLA Navy, Qingdao, China.
出版信息
Pathol Res Pract. 2022 Nov;239:154168. doi: 10.1016/j.prp.2022.154168. Epub 2022 Oct 13.
Gliomas are common brain tumors with poor prognosis. F-box protein39 (FBXO39) is found to be increased in a variety of malignancies, but its expression in gliomas is unknown. Here, we report that FBXO39 as an oncogene is upregulated in glioma and associated with poor prognosis. The degree of FBXO39 positive expression is doubtlessly concomitant with the grade of glioma. The data analyses show that patients with high FBXO39 expression have poor overall survival. What's more, FBXO39 accelerates the invasion and migration abilities of glioma cells and promotes glioma stem cell growth and stemness. In summary, these results suggest that FBXO39 is expected to become a new biological target for judging the prognosis and treatment of glioma.
神经胶质瘤是一种常见的预后不良的脑肿瘤。研究发现 F-box 蛋白 39（FBXO39）在多种恶性肿瘤中增加，但在神经胶质瘤中的表达尚不清楚。在这里，我们报告 FBXO39 作为一种癌基因在神经胶质瘤中上调，并与不良预后相关。FBXO39 阳性表达的程度无疑与神经胶质瘤的分级相关。数据分析表明，FBXO39 高表达的患者总体生存不良。更重要的是，FBXO39 加速了神经胶质瘤细胞的侵袭和迁移能力，并促进了神经胶质瘤干细胞的生长和干性。总之，这些结果表明 FBXO39 有望成为判断神经胶质瘤预后和治疗的新的生物学靶点。
Zotero 插件